Management across settings: An ambulatory and community perspective for patients undergoing car t-cell therapy in multiple care settings

Alix Beaupierre, Rachel Lundberg, Leslie Marrero, Michael Jain, Trent Wang, Maritza C. Alencar

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

BACKGROUND: Many patients are referred to chimeric antigen receptor (CAR) T-cell therapy programs from outside their primary oncology setting and community. Collaboration between the referring and treating providers is required to coordinate safe and effective care. OBJECTIVES: This article presents an overview of key considerations for referring providers and institutions prior to and following CAR T-cell therapy. METHODS: Definitions of the consultation and workup, leukapheresis, bridging, lymphodepleting chemotherapy, infusion and monitoring, and longterm follow-up phases are presented, along with specific considerations for referring centers. FINDINGS: Although CAR T-cell therapy is limited to select centers, the process of supporting and educating patients and their caregivers requires a partnership between referring and treating providers. As CAR T-cell indications expand, management of patients in diverse settings requires a collaborative and evidence-based approach to support safe and effective care.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalClinical Journal of Oncology Nursing
Volume23
Issue number2
DOIs
StatePublished - Apr 2019

Keywords

  • Car t-cell therapy
  • Care coordination
  • Community-based care
  • Referring centers

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Fingerprint

Dive into the research topics of 'Management across settings: An ambulatory and community perspective for patients undergoing car t-cell therapy in multiple care settings'. Together they form a unique fingerprint.

Cite this